Parallax Volatility Advisers
BPMC

Parallax Volatility Advisers’s Blueprint Medicines BPMC Stock Holding History

Parallax Volatility Advisers’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-22,500
Closed -$1.42M – 2303
2023
Q2 		$1.42M Buy
+22,500
New +$1.22M ﹤0.01% 1267
2019
Q1 		– Sell
-15,000
Closed -$809K – 2807
2018
Q4 		$809K Hold
15,000
– – ﹤0.01% 1379
2018
Q3 		$1.17M Hold
15,000
– – ﹤0.01% 1212
2018
Q2 		$952K Buy
+15,000
New +$1.19M ﹤0.01% 1110

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Parallax Volatility Advisers's BPMC Position: Q3 2019 in Review

Parallax Volatility Advisers sold out of Blueprint Medicines (BPMC) in Q3 2019, closing a stake of 616 shares — an estimated $58K sold.

Parallax Volatility Advisers first reported a position in BPMC in Q4 2017 and held it in 5 quarters. The position peaked at $650K in Q4 2018. 220 funds tracked by Wall St. Rank hold BPMC as of Q3 2019.

  • Parallax Volatility Advisers reported no remaining Blueprint Medicines position as of Q3 2019 after selling out during the quarter.
  • Parallax Volatility Advisers sold 616 Blueprint Medicines shares in Q3 2019, an estimated $58K.
  • Parallax Volatility Advisers first reported a position in Blueprint Medicines in Q4 2017 and held it in 5 quarters.
  • Parallax Volatility Advisers's Blueprint Medicines position peaked at $650K in Q4 2018.
  • 220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2019.

Based on Parallax Volatility Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.